Topic Hub

Ethnicity Lemborexant

4 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.

4articles

25keywords mapped

2025-01-28latest review

Explore

Ethnicity Lemborexant library

Showing 4 of 4 clinical reviews.

Dosing & Monitoring2025-01-28

Dayvigo (Lemborexant) Dosing in Black and African Ancestry Patients: What the Evidence Actually Shows

A clinician-facing review of lemborexant pharmacogenomics, SUNRISE trial subgroup data, and practical dose-adjustment guidance for patients of Black or African ancestry.

Read clinical review

Dosing & Monitoring2025-01-28

Dayvigo (Lemborexant) Dosing in Hispanic / Latino Patients: What the Evidence Shows

A clinical deep-dive into lemborexant pharmacokinetics, CYP3A4 variant prevalence, and dose-adjustment considerations specific to Hispanic / Latino patients, reviewed by the HealthRX.com medical team.

Read clinical review

Clinical Reviews2026-05-27

Dayvigo (Lemborexant) in South Asian Patients: Documented Efficacy Gaps and Pharmacogenomic Considerations

South Asian patients may respond differently to lemborexant (Dayvigo) due to CYP3A4 polymorphisms, body composition differences, and underrepresentation in key trials. This article reviews available ethnicity-stratified data, pharmacogenomic factors, and practical dosing guidance.

Read clinical review

Questions2025-01-15

Dayvigo East Asian Documented Efficacy Gaps: What the Data Actually Show

A clinical deep-dive into lemborexant (Dayvigo) efficacy and pharmacokinetic differences in East Asian patients, covering CYP2C19 polymorphisms, SUNRISE trial subgroup data, and practical dosing guidance.

Read clinical review